Stable disease signal pushes Amgen KRAS inhibitor forward in colorectal cancer

Despite a far lower partial response rate in colorectal cancer than in lung cancer, Amgen plans to expand its colorectal trials and gear up for combination studies of closely watched KRAS inhibitor AMG 510, citing an impressive stable disease signal.

At the European Society for Medical Oncology (ESMO) meeting on Saturday, Amgen Inc. (NASDAQ:AMGN) reported one of the 12 (8%) colorectal cancer patients on the highest dose of 960 mg achieved a partial response in the Phase I dose escalation trial to treat KRAS G12C mutant solid tumors at the six week scan...